Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

Showing session: reset

Plenary Session 8: Combining Immunotherapies, Immune Modulators, and Targeted Therapies: Regulatory Opportunities and Challenges

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 7 of 7
Plenary Session 8: Combining Immunotherapies, Immune Modulators, and Targeted Therapies: Regulatory Opportunities and Challenges
Introductions
F. Stephen Hodi
Dana-Farber Cancer Inst., Boston, MA, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 23, 2013 10:30 AM-12:30 PM
Plenary Session 8: Combining Immunotherapies, Immune Modulators, and Targeted Therapies: Regulatory Opportunities and Challenges
Regulatory Perspectives and Updates
Ke Liu
U.S. Food and Drug Administration, Rockville, MD, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 23, 2013 10:30 AM-12:30 PM
Plenary Session 8: Combining Immunotherapies, Immune Modulators, and Targeted Therapies: Regulatory Opportunities and Challenges
Engaging an adaptive immune response in cancer
Michael A. Postow
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 23, 2013 10:30 AM-12:30 PM
Plenary Session 8: Combining Immunotherapies, Immune Modulators, and Targeted Therapies: Regulatory Opportunities and Challenges
A pharmaceutical development point of view
Renzo Canetta
Bristol-Myers Squibb Co., Wallingford, CT, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 23, 2013 10:30 AM-12:30 PM
Plenary Session 8: Combining Immunotherapies, Immune Modulators, and Targeted Therapies: Regulatory Opportunities and Challenges
Melanoma Research Alliance: Investing in innovation
Louise M. Perkins
Melanoma Research Alliance, Washington, DC, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 23, 2013 10:30 AM-12:30 PM
Plenary Session 8: Combining Immunotherapies, Immune Modulators, and Targeted Therapies: Regulatory Opportunities and Challenges
Panel Discussion
F. Stephen Hodi
Dana-Farber Cancer Inst., Boston, MA, United States
Ke Liu
U.S. Food and Drug Administration, Rockville, MD, United States
Michael A. Postow
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
Renzo Canetta
Bristol-Myers Squibb Co., Wallingford, CT, United States
Louise M. Perkins
Melanoma Research Alliance, Washington, DC, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 23, 2013 10:30 AM-12:30 PM
Plenary Session 8: Combining Immunotherapies, Immune Modulators, and Targeted Therapies: Regulatory Opportunities and Challenges
Panel: Audience Q & A
F. Stephen Hodi
Dana-Farber Cancer Inst., Boston, MA, United States
Ke Liu
U.S. Food and Drug Administration, Rockville, MD, United States
Michael A. Postow
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
Renzo Canetta
Bristol-Myers Squibb Co., Wallingford, CT, United States
Louise M. Perkins
Melanoma Research Alliance, Washington, DC, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 23, 2013 10:30 AM-12:30 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 7 of 7